COMPARATIVE STUDY OF PHASE III RANDOMIZED, DOUBLE-BLIND TWO REGIMES OF DOSE OF MICAFUNGIN (FK463) VERSUS CASPOFUNGIN FOR THE TREATMENT OF CANDIDIASTIC ESOPHAGITIS

FUJISAWA HEALTH CARE INC,0 个研究点目标入组 0 人开始时间: 2004年5月25日最近更新: 2023年9月4日

适应症

试验速览

暂无简介。

•1. The informed consent of the patient or his legally authorized representative must be obtained before entering the study.
•2. Patients can be of both sexes.
•3. Patients 16 years of age or older.
•4. The patient must have candidiasic esophagitis confimiada within 5 days prior to the administration of the first dose of the study drug.

•1. Pregnant or nursing patient.
•2. Evidence of liver disease
•3. Patients with another active opportunistic fungal infection and / or who receive acute systemic therapy for an opportunistic fungal infection.
•4. Patients with concomitant esophagitis caused by herpes simplex virus or cytomegalovirus or other causes of irritant esophagitis that could interfere with the evaluation of clinical signs and symptoms.
•5. Patients who received an oral, nonabsorbable (topical) antifungal agent within 48 hours, or a systemic antifungal agent within 72 hours prior to the initial dose of the study drug.
•6. Patients that require an oral, nonabsorbable (topical) or systemic antifungal agent for a condition other than candidiasis esophagitis.

发起方

FUJISAWA HEALTH CARE INC,